Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane for treatment-resistant depression
NCT05008939Unknown
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of sevoflurane in major depressive disorder (MDD), sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoint: Hamilton Depression Rating Scale Response at 24 hours. Status: unknown.
02
Drugs
sevoflurane
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05008939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008939.